TrialImmunoHorizons2025

Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization.

Phillip Scheinberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.